Home / Workshop Program

Workshop Program

The event will operate on Queensland time / AEST / UTC+10h / GMT+10h
The workshop’s hourly schedule will be set closer to the workshop date, after venue arrangements have been made.

 

27th of April 2018

TimeTitle & SpeakerDuration
The International Quality Network for Pathology (IQN-Path) update
John Garratt, Canadian Immunohistochemistry Quality Control (cIQc), Vancouver Canada
A National Population-based Approach to Laboratory Quality Improvement
Niall Swan, St Vincent’s University Hospital and UCD School of Medicine, Dublin, Ireland
RCPAQAP Update and the Challenges of implementing PD-L1 EQA
Julia Pagliuso, RCPAQAP, St Leonards NSW, Australia
Review of results of ALK EQA over 2 years
Zenobia Haffajee, RCPAQAP, St Leonards NSW, Australia
TMA based external quality assurance, the cIQc programme.
John Garratt, Canadian Immunohistochemistry Quality Control (cIQc), Vancouver Canada
Biobanking and quality assurance management relevant to IHC: a North American perspective
Christopher Andry, Boston University Medical Center, Boston, USA
An update on Australian medical laboratory accreditation requirements.
Gillian Treloar, NATA (National Association of Testing Authorities, Australia), Melbourne, Australia
 

28th of April 2018

TimeTitle & SpeakerDuration
A Window Onto the Molecular Biology of Tumors
Allen Gown, PhenoPath and Fred Hutchinson Cancer Research Center, Seattle, USA: Next Generation Immunohistochemistry
The role of p16 immunohistochemistry in head and neck tumor diagnosis and management
Jane Dahlstrom, ACT Pathology, Canberra University Hospital and Australian National University Medical School, Australia
Using a IHC panel in colorectal cancer biopsies to optimize patient management: An update
Kieran Sheahan, St Vincent’s Univesity Hospital and UCD School of Medicine, Dublin, Ireland
Doing it right – Mismatch repair (MMR) for determining eligibility for immuno-modulator therapy
John Garratt, Canadian Immunohistochemistry Quality Control (cIQc), Vancouver Canada
Standardization and optimization of antibodies in gastrointestinal cancer diagnosis
Nathan Acott, PathWest Laboratory Medicine, Nedlands WA, Australia
Standardization and optimization of B-Raf v600e
John Garratt, Canadian Immunohistochemistry Quality Control (cIQc), Vancouver Canada
The detection of tumor budding by H&E & IHC improves patient stratification in colorectal cancer.
Kieran Sheahan, St Vincent’s Univesity Hospital and UCD School of Medicine, Dublin, Ireland
Tests Predictive of Response to PD-L1 and PD-1 Targeted Therapies
Allen Gown PhenoPath and Fred Hutchinson Cancer Research Center, Seattle, USA
From the Newfoundland scandal to present day – Optimization of breast biomarker testing in Canada
John Garratt, Canadian Immunohistochemistry Quality Control (cIQc), Vancouver Canada
The role of IHC in breast cancer diagnosis and optimization of patient management
Emiel Janssen, Stavanger University Hospital, Norway:
Standardization and optimization of antibodies in breast cancer diagnosis
Nathan Acott, PathWest Laboratory Medicine, Nedlands WA, Australia
Immunohistochemistry in Endocrine Tumours, a Diagnostic and Theranostic Role
Niall Swan, St Vincent’s Univesity Hospital and UCD School of Medicine, Dublin, Ireland
Standardization and optimization in lung cancer diagnosis
John Garratt, Canadian Immunohistochemistry Quality Control (cIQc), Vancouver Canada
Standardization and optimization of antibodies in lung cancer diagnosis
Nathan Acott, PathWest Laboratory Medicine, Nedlands WA, Australia
 

29th of April 2018

TimeTitle & SpeakerDuration
The role of Immunohistochemistry in the diagnosis and management of unknown soft tissue tumours.
John Slavin, St Vincent’s Univesity Hospital, VIC Melbourne, Australia
Rationale and Cost-Effective Use of Antibody Panels in Immunohistochemistry: Allen Gown, PhenoPath Seattle
Allen Gown, PhenoPath and Fred Hutchinson Cancer Research Center, Seattle, USA
Introducing iCAPCs (Immunohistochemistry Critical Assay Performance Controls )
John Garratt, Canadian Immunohistochemistry Quality Control (cIQc), Vancouver Canada
Digital Immunohistochemistry and Personalized Medicine in Norway.
Emiel Janssen, Stavanger University Hospital, Norway
Digital and quantitative immunohistochemistry in Bladder cancer
Emiel Janssen, Stavanger University Hospital, Norway
Specimen quality and pre-analytic variables
Christopher Andry, Boston University Medical Center, Boston, USA
The crispy brown stain in IHC – can it be misleading; Errors made and lessons learnt
Beena Kumar, Monash Medical Centre, Melbourne, VIC, Australia
Immunohistochemistry- Headaches Heartbreaks and Heroics
David Gan, QML Pathology Brisbane and RCPASQAP St Leonards NSW, Australia